Xencor

Update in progress

XNCR (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Xencor, Inc. is a clinical‑stage biopharmaceutical company focused on engineered antibodies for cancer and autoimmune diseases. Its XmAb–based pipeline includes Ultomiris, Monjuvi, and XmAb819 through XmAb942, Plamotamab, XmAb657, Xaluritamig, ASP2138, JNJ‑9401, Obexelimab, Tobevibart, Zaltenibart, Teropavimab, zinlirvimab, and related collaborations. Founded in 1997, the company is headquartered in Pasadena, California.

Company score

Sentiment: 0.49; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.30; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.11; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.30; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive